In this Review:
Immunotherapy
PD-L1 expression and efficacy of pembrolizumab vs. ipilimumab for advanced melanoma
Differences in anti-PD1 toxicity patterns among tumour streams
Estimating survival with targeted/immunotherapies for metastatic melanoma
Pembrolizumab vs. ipilimumab for advanced melanoma: final OS
Nonmelanoma solid tumours outcomes for self-funded pembrolizumab
Miscellaneous topics
Fulvestrant for hormone-sensitive advanced breast cancer
Oncologists’ preferences for recommending expensive anticancer drugs
Impact of chemotherapy on cognition in testicular cancer
Docetaxel-related fatigue in metastatic prostate cancer
Chemotherapy prescribing for older cancer patients
Please login below to download this issue (PDF)